



Hybrid Agents for Multimodal Imaging

Guest Editors:

Prof. Dr. Carmen Wängler

Biomedical Chemistry, Clinic of
Radiology and Nuclear Medicine,
Medical Faculty Mannheim,
Heidelberg University, 68167
Mannheim, Germany

Dr. Ralph Hübner

Medical Faculty Mannheim,
Heidelberg University,
Mannheim, Germany

Deadline for manuscript
submissions:

closed (25 February 2022)

Message from the Guest Editors

The journal *Pharmaceuticals* is planning to publish a Special Issue, Hybrid Agents for Multimodal Imaging, and I am cordially inviting you to contribute an article to this volume, describing your latest research and, of course, reviews are welcome as well.

The use of imaging to visualize and characterize a wide variety of diseases is deeply embedded in routine clinical practice. In addition to conventional imaging, the combination of imaging modalities is of increasing relevance and an increasing number of complementary combinations are being used to the benefit of patients. For this reason, a growing field of research has been focusing for several years on the development of combined or combinable contrast agents that can be detected using multiple imaging modalities, thus allowing a complementary gain of information.

The goal of this Special Issue is to gather the latest developments in this area of hybrid imaging agent development for multimodal imaging to provide the most complete coverage of this exciting and forward-looking area of research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com